Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocMorris AGXSWX:DOCM -5.94%65 3-Year Revenue Growth Rate is -21.60% as of Jun. 2025. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.70 (Fairly Valued). The stock has 8 warning signs investors should review. Among 612 Healthcare Providers & Services companies, DocMorris AG ranks worse than 92.65% on this metric.
During the past 12 months, DocMorris AG's average Revenue per Share Growth Rate was -22.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -15.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -10.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of DocMorris AG was 35.70% per year. The lowest was -21.60% per year. And the median was -7.55% per year.
DocMorris AG (XSWX:DOCM) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
DocMorris AG 3-Year Revenue Growth Rate Related Terms
DocMorris AG 3-Year Revenue Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, DocMorris AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG 3-Year Revenue Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where DocMorris AG's 3-Year Revenue Growth Rate falls into.
DocMorris AG 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of -21.60% mean?
DocMorris AG (XSWX:DOCM) has a 3-Year Revenue Growth Rate of -21.60% as of Jun. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for DocMorris AG and its competitors. According to the industry distribution chart, DocMorris AG ranks #567 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 92.6%.
Is DocMorris AG's 3-Year Revenue Growth Rate too high?
DocMorris AG's current 3-Year Revenue Growth Rate is -21.60%. Based on the distribution chart, DocMorris AG ranks #567 out of 612 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's 3-Year Revenue Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #567 out of 612 companies for 3-Year Revenue Growth Rate. This places DocMorris AG in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Healthcare Providers & Services company?
The median 3-Year Revenue Growth Rate among Healthcare Providers & Services companies is 6.90, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year Revenue Growth Rate is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current 3-Year Revenue Growth Rate is -21.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Fairly Valued. The stock's GF Value™ is CHF10.70, compared to a current price of CHF9.82 — trading 8.2% below its estimated fair value. The current 3-Year Revenue Growth Rate is -21.60%. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current 3-Year Revenue Growth Rate is -21.60% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF9.82 is trading 8.2% below its estimated GF Value™ of CHF10.70.
GuruFocus considers DocMorris AG to be Fairly Valued.
Key valuation signals for XSWX:DOCM:
3-Year Revenue Growth Rate: -21.60%
GF Value™: CHF10.70 vs. price of CHF9.82 (8.2% below fair value)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
